ofatumumab
Selected indexed studies
- Ofatumumab versus Teriflunomide in Multiple Sclerosis. (N Engl J Med, 2020) [PMID:32757523]
- Ofatumumab. (Drugs, 2010) [PMID:20481657]
- Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. (Mult Scler, 2023) [PMID:37691530]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ofatumumab versus Teriflunomide in Multiple Sclerosis. (2020) pubmed
- Ofatumumab. (2010) pubmed
- Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. (2023) pubmed
- Ofatumumab-exposed breastfeeding in multiple sclerosis patients. (2025) pubmed
- Ofatumumab. (2009) pubmed
- Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. (2018) pubmed
- Ofatumumab. (2020) pubmed
- Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. (2024) pubmed
- Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. (2022) pubmed
- Ofatumumab for relapsing forms of multiple sclerosis. (2022) pubmed